481 Pityriasis rubra pilaris transcriptomics further implicate IL-17 signaling and correlate with response to IL-17A inhibitor therapy

Abstract

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder associated with significant patient morbidity. The pathophysiology of PRP has been under ongoing investigation with studies implicating alterations in Th17 signaling, phospholipase processing, and novel germline CARD14 gene variations. In this study, 11 patients with moderate-to-severe PRP (as defined by a Psoriasis Area and Severity Index [PASI] ≥ 10) had lesional skin biopsies taken prior to and following 24 weeks of Il-17A inhibitor therapy for RNA sequencing analysis.